Expertise in
29
conditions

Dr. Isam A. Diab

Rheumatology
25200 Ctr Ridge Rd, Suite 2400, 
Westlake, OH 
Accepting New Patients
Expertise in
29
conditions
25200 Ctr Ridge Rd, Suite 2400, 
Westlake, OH 

Overview

Isam Diab is a Rheumatologist in Westlake, Ohio. Dr. Diab is highly rated in 29 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Vitamin D Deficiency, Polymyalgia Rheumatica, and Rhizomelic Pseudopolyarthritis. Dr. Diab is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in OH

Hospital Affiliations

Southwest General Health Center

Languages Spoken

English
Arabic
Arabic - Jordanian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 24 Less Insurance Carriers -

Locations

PREMIER PHYSICIANS CENTERS INC
25200 Ctr Ridge Rd, Suite 2400, Westlake, OH 44145
Other Locations
PREMIER PHYSICIANS CENTERS INC
18660 Bagley Rd, Bldg 2, Middleburg Heights, OH 44130
PREMIER PHYSICIANS CENTERS INC
24500 Ctr Ridge Rd, Suite 375, Westlake, OH 44145

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Vectra InVolved Informed Decision Outcome Study (VIVID): A Prospective Randomized Controlled Trial Evaluating the Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
Vectra InVolved Informed Decision Outcome Study (VIVID): A Prospective Randomized Controlled Trial Evaluating the Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Diagnostic test
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 17, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 12, 2023
Intervention Type: Drug
Study Drug: LY3462817
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

1 Total Publications

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
Journal: Journal of translational autoimmunity
Published: February 13, 2022
Similar Doctors
Patompong Ungprasert
Expertise in
30
conditions
Dr. Patompong Ungprasert
Rheumatology
Expertise in
30
conditions
Dr. Patompong Ungprasert
Rheumatology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (14.7 miles away)
216-445-4745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patompong Ungprasert is a Rheumatologist in Cleveland, Ohio. Dr. Ungprasert is highly rated in 30 conditions, according to our data. His top areas of expertise are Sarcoidosis, Neurosarcoidosis, Vasculitis, Endoscopy, and Sleeve Gastrectomy.

Soumya Chatterjee
Expertise in
34
conditions
Dr. Soumya Chatterjee
Rheumatology
Expertise in
34
conditions
Dr. Soumya Chatterjee
Rheumatology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (14.9 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Soumya Chatterjee is a Rheumatologist in Cleveland, Ohio. Dr. Chatterjee is highly rated in 34 conditions, according to our data. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleredema, and Raynaud Phenomenon.

Rula Hajj
Expertise in
35
conditions
Dr. Rula Hajj
Rheumatology
Expertise in
35
conditions
Dr. Rula Hajj
Rheumatology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (14.9 miles away)
216-444-2200
Experience:
37+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rula Hajj is a Rheumatologist in Cleveland, Ohio. Dr. Hajj has been practicing medicine for over 37 years is highly rated in 35 conditions, according to our data. Her top areas of expertise are Vasculitis, Granulomatosis with Polyangiitis, Scleritis, and Goodpasture Syndrome.

Frequently Asked Questions about Dr. Isam A. Diab

How do I make an appointment with Dr. Isam A. Diab?

You can book an appointment with Dr. Isam A. Diab by calling their office at 440-333-3332. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Isam A. Diab a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Isam A. Diab is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Isam A. Diab specialize in?

While Dr. Isam A. Diab is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Vitamin D Deficiency, and Polymyalgia Rheumatica. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Isam A. Diab participate in research or clinical trials?

Yes. Dr. Isam A. Diab has published 1 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Isam A. Diab's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Isam A. Diab accept my insurance?

Dr. Isam A. Diab accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 440-333-3332 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Diab's expertise for a condition
ConditionClose
    View All 25 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile